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Abstract
Background: We intended to estimate the proportion hypoglycemic/hyperglycemic emergency episodes in
treated diabetes mellitus (DM) patients admitted to a hospital ward, and calculate the prevalence of risk factors for
hypoglycemia and diabetic complications.
Methods: In this cross-sectional, multicentered study, the observational data was collected by physicians from
patient’s hospitalization to discharge/death. Statistical tests were 2-tailed considering 5% significance level.
Results: There were 646 ward admissions due to hyperglycemic emergencies and 176 hypoglycemic episodes with
a ratio hypoglycemia/hyperglycemia 0.27 for all DM patients. In T2DM patients the ratio was 0.38. These were
mainly female (55.1%), functionally dependent (61.4%) and retired/disabled (73.1%). Median age was 75 years and
median duration of disease 11 years. Half the patients were on insulin-based therapy and 30.1% on secretagogue-
based therapy. Approximately 57% of patients needed occasional/full assistance to manage the disease. The most
frequent risk factor for hypoglycemia was polypharmacy (85.0%). Hypoglycemia in the 12 months before admission
was higher in insulin-based therapy patients (66.1%; p = 0.001).
Conclusions: Hyperglycemic emergencies are the most frequent cause of hospitalization in Portugal, although
severe hypoglycemic events represent a health and social problem in elderly/frail patients. There is still the need to
optimize therapy in terms of the potential for hypoglycemia in this patient group and a review of anti-
hyperglycemic agents to add on to insulin.
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Introduction
Diabetes mellitus (DM) is a chronic disease, characterized
by hyperglycemia due to insulin deficiency, insulin resist-
ance, or both [1, 2]. In Portugal the estimated prevalence
of DM among adults (20–79 years) is 13.3% [3]. The rela-
tionship between the burden of hypoglycemia and hyper-
glycemia has been shifting and evolving [4, 5]. Achieving
HbA1c targets < 7% (53mmol/mol) has been shown to
reduce microvascular complications of both type 1 and
type 2 diabetes when instituted early in the course of
disease [6]. International guidelines recommend lowering
HbA1c to < 7.0% in most patients and to keep glycemic
control well balanced and managed [7, 8]. However
caution is needed in treating diabetes aggressively to near
normal HbA1c goals in people with advanced age/frailty,
with longstanding type 2 diabetes with or at significant
risk of cardiovascular disease. Hypoglycemia is a limiting
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factor in achieving glycemic control and often related to
poor clinical outcomes in patients with DM, making it
difficult to manage [9–11]. Sometimes requiring assist-
ance/hospitalization, hypoglycemia has a significant
impact in patients’ lives. Typically, hyperglycemia related
admissions (diabetes ketoacidosis (DKA), hyperglycemic
hyperosmolar non-ketotic syndrome (HHNS)) are the
major cause of DM related admissions in non-surgical
wards. In the last decade there has been an increasing
drive to improve glycemic target achievement with mean
HbA1c at the primary care level dropping from 7.8% in
2010 to 6.8% in 2015 [3, 12]. While lowering HbA1c
might be associated with an increase in the risk of
hypoglycemia, Portugal has had a high uptake of innova-
tive anti-hyperglycemic agents associated with lower risk
of hypoglycemia (DPP4 inhibitors, SGLT2 inhibitors and
GLP1 analogues) and a decrease in the use of sulphony-
lurea (SU) [3]. It is unclear if this trend impacted diabetes
admissions.
Data from HIPOS-ER (HIPOS-Emergency Room) [13, 14]
showed that 44.1% of patients with type 2 diabetes (T2DM)
admitted to the emergency room with hypoglycemic
episodes due to anti-hyperglycemic therapy were admitted to
internal medicine/endocrinology wards, and discharged after
5 days on average. Results confirmed that hypoglycemia
places a significant burden both to patient and society,
accounting for adverse clinical and financial outcomes. In
Portugal there is still a gap in the understanding of
hypoglycemia admissions, hypoglycemia risk factors, and
how they have evolved since the data from HIPOS-ER
increased awareness of the magnitude of the problem.
This observational study aimed to evaluate the ratio of
DM patients admitted in the ward due to hypoglycemia
episodes vs. hyperglycemic emergencies, to calculate the
prevalence of previously described hypoglycemia risk
factors and diabetic complications in this population and
to characterize patients by treatment group and type of
diabetes.
Materials and methods
The observational, cross-sectional, multicentered
HIPOS-WARD (Hypoglycemia In Portugal Observa-
tional Study – WARD) study primarily assessed the
proportion of hypoglycemic and hyperglycemia emer-
gency episodes in DM treated adult patients that
accounted for the admission to an endocrinology/in-
ternal medicine ward due to hypoglycemia. The pro-
portion of hypoglycemia/hyperglycemia emergency
episodes was also evaluated for T2DM patients.
Patients with diabetes and a hypoglycemic episode were
characterized demographically and clinically (type and
duration of diabetes, treatment group, diabetes complica-
tions, comorbidities, history of hypoglycemia, HbA1c,
glycemia, repeated episodes during hospitalization). The
prevalence of previously described hypoglycemia risk factors
and diabetic complications were also calculated as well as
hypoglycemia literacy of patients. Exploratory analyses by
treatment group and type of diabetes were performed.
The study population included adult (≥18 years old)
patients with diabetes treated with a known anti-
hyperglycemic agent, hospitalized in the ward for a
hypoglycemia event or as a result of a hypoglycemia
episode in the non-hospitalized setting, in one of the 16
participating medical units (18 departments).
Hypoglycemia was defined according to the American
Diabetes Association (ADA) [15, 16] definition of a
modified Whipple’s triad (signs and symptoms suggest-
ive of hypoglycemia that resolve with the administration
of carbohydrates or glucagon and a glycemia < 70 mg/
dL). Diagnosis was made by the attending ER physician,
and ward admission was considered if: patients were
admitted from the ER due to hypoglycemia; and/or
patients that had an episode of hypoglycemia while at
the hospital (outpatient clinic/other non-hospitalized
setting) were admitted as a direct result of that
hypoglycemia. Hospitalization was considered for
patients admitted for at least 24 h for diagnosis/
treatment.
Hospitalized hyperglycemic emergencies included
DKA, HHNS and significant hyperglycemia. DKA and
HHNS were defined according to ADA’s criteria [17].
Significant hyperglycemia was defined as glycemia ≥600
mg/dL or clinical symptoms (polyuria, polydipsia).
Hyperglycemic emergencies were used to calculate the
ratio hypoglycemia/hyperglycemia and not further
assessed in this study.
Hypoglycemia literacy was evaluated by a non-
validated questionnaire created and performed by the
investigator to the patient/caregiver (if the patient was
unable). Questions focused on the knowledge of the
signs and symptoms of hypoglycemia and knowledge of
strategies to prevent hypoglycemia.
Treatment subgroups were classified according to
the anti-hyperglycemic agent therapy regimen: i)
insulin-based therapy (included patients on insulin
monotherapy/on insulin with or without other non-
secretagogue drugs); ii) secretagogue-based regimen
(included patients on secretagogue monotherapy
(sulphonylurea and/or meglitinides), with/without
other non-secretagogue drugs); iii) non-secretagogue-
based therapy (included patients on drugs that do
not include a secretagogue type drug (i.e. metformin,
acarbose, glitazones, DPP4 inhibitors, GLP1 receptor
agonists, SGLT2 inhibitors)); iv) combination of
insulin and secretagogue (included patients that were
treated with at least one insulin and one secreta-
gogue type drug (other drugs may have been
present)).
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The total study duration was 21 months (Novem-
ber2016–August2018).
All study procedures were performed under standard
clinical approach. Observational study data was collected
by physicians from hospitalization admission to
discharge or death. Data collected included sociodemo-
graphic, anthropometrics; diabetes characterization, risk
factors; characterization of hypoglycemia episode;
hypoglycemia literacy evaluation; laboratory and diag-
nostic exams; and discharge information.
The study was approved by the Hospital’s or local
Ethics Committees and by the National Committee for
Data Protection. Written informed consent was obtained
from all participants.
Statistical methods
Data were summarized using descriptive statistics (mean,
standard deviation, median, minimum and maximum for
quantitative variables; counts and percentages for qualita-
tive variables). Missing values were not replaced. Percent-
ages were calculated based on non-missing values.
The ratio of ward admissions due to hypoglycemia per
hyperglycemic emergencies was estimated with corre-
sponding 95% confidence interval (CI). The comparisons
of anti-hyperglycemic agent therapy classes or type of
diabetes were performed with Chi-square test, Fisher’s
exact test or Monte Carlo methods (if assumptions were
not met) for categorical variables. Quantitative variables
were compared using ANOVA or Mann-Whitney test
and Kruskal-Wallis test, if assumptions were not met.
Statistical tests were 2-tailed considering 5% signifi-
cance level. Statistical analyses were performed using




A total of 646 ward admissions were registered due
to hyperglycemic emergencies (328 DKA, 203 HHNS,
115 significant hyperglycemias) in all patients with
diabetes. In the same period, there were 176 ward
admissions due to hypoglycemia episodes in DM patients.
The ratio hypoglycemia/hyperglycemia was 0.27 (95%CI =
0.23;0.32) for all DM patients. Considering T2DM patients,
there were 404 hyperglycemic emergencies and 152
hypoglycemia episodes, in a ratio of 0.38 (95%CI = 0.31;0.45).
Baseline characterization
The 176 ward admissions due to hypoglycemia episodes
are the focus of this analysis. Half the patients included
in the study were on insulin-based therapy (50.0%),
30.1% were on secretagogue-based therapy, 9.7% on
non-secretagogue therapy and 10.2% on insulin+secreta-
gogue therapy. The sample was mainly female (55.1%)
with median age of 75 years and mean body mass index
(BMI) 26.0 kg/m2. A statistically significant association
was found between treatment groups and median age
(p = 0.009, insulin+secretagogue and secretagogue
patients with higher values) and with BMI (p = 0.032,
secretagogue-based patients had higher BMI). Approxi-
mately 19% of patients were institutionalized and 23% of
the non-institutionalized were living alone. Most of the
patients (73.1%) were retired/disabled and only 9.2%
were working full or part time. The hypoglycemia
episodes occurred mainly in T2DM patients (86.4%),
with a median duration of disease of 11 years. More than
half of patients needed occasional (27.8%) or full (29.5%)
assistance to manage the disease, 61.4% were function-
ally dependent. The proportion of patients followed in
primary health care was statistically higher (p < 0.001) in
patients with secretagogue-based therapy (94.3%), com-
pared to the other groups of treatment. Patients on insu-
lin+secretagogue and insulin-based therapy had a higher
median disease duration (p < 0.001). Half of the sample
suffered from chronic diabetes complications related
with the eye (50.0%: mostly retinopathy), atherosclerotic
disease (47.8%: mostly peripheral artery disease) or
nephropathy (47.4%: mean creatinine: 2.58 mg/dl; mean
eGFR: 41.15 ml/min/1.73m2; mean eGFR basal: 47.60
ml/min/1.73m2; mean albumin: 248.42 μg/mg; median
proteinuria: 344.00 mg). Presence of eye complications
was higher in patients on insulin-based therapy (62.3%;
p = 0.011). Other complications were not statistically dif-
ferent between treatment groups. HbA1c (p < 0.001) and
the lowest glycemia (p = 0.041) in the ward showed sta-
tistically significant differences between groups: insulin-
based patients had highest median HbA1c (7.6%) and in-
sulin+secretagogue patients the highest median lowest
glycemia (91.5 mg/dL). Approximately 48% of the
patients had a hypoglycemia in the previous 12months
(mean 2.2 events/patient required assistance from other
person; mean 0.5 events/patient pre-hospital assistance;
mean 0.7 events/patient ER assistance). From those,
70.4% had hypoglycemia in the previous 30 days. One
episode occurred while the patient was driving. The pro-
portion of patients with hypoglycemia in the 12months
previous to admission was higher in patients on insulin-
based therapy (66.1%) with statistically significant
differences (p = 0.001) (Table 1).
Hypoglycemia episode characterization
The most frequent triggering causes of hypoglycemia
were carbohydrate deficit (including ‘missed or delayed
meal’ and ‘meal inappropriately low in carbohydrates’)
(54.0%), acute illness (40.2%) and related to insulin ther-
apy (34.3%). As determined by the investigators, approxi-
mately 15% of patients had associated complications as a
result of hypoglycemia, most frequently neurologic and
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infectious complications (3 aspiration pneumonias, 2
lower urinary tract infections, 1 pyelonephritis, 1 sepsis
and 1 conjunctivitis).
The median lowest glycemia recorded at ER admission
or pre-hospital was 40.0 mg/dL (9.0–298.0 mg/dL) and
74.0 mg/dL (20.0–268.0 mg/dL) in the ward. A total of
Table 1 Baseline patient’s characteristics, overall and by class of anti-hyperglycemic agent
Total
(n = 176)














Gender (female), n(%) 97 (55.1) 42 (47.7) 33 (62.3) 11 (64.7) 11 (61.1) 0.269a
Age, median (min;max), (years) 75.0 (28;98) 73.5 (28;92) 78.0 (50;96) 72.0 (45;98) 78.5 (58;88) 0.009b
BMI, mean (SD), (kg/m2) 26.0 (4.6) 25.2 (4.7) 27.4 (4.3) 25.8 (4.7) 25.5 (4.6) 0.032b
Patient institutionalized, n(%) 33 (18.8) 13 (14.8) 11 (20.8) 2 (11.8) 7 (38.9) 0.122c
Patient lives alone, n(%) 33 (23.1) 19 (25.3) 8 (19.0) 4 (26.7) 2 (18.2) 0.880c
Work status, n(%) 0.015c
Full time 15 (8.6) 14 (16.1) 0 (0.0) 1 (5.9) 0 (0.0)
Partial time 1 (0.6) 0 (0.0) 1 (1.9) 0 (0.0) 0 (0.0)
Retired/disabled 128 (73.1) 55 (63.2) 46 (86.8) 11 (64.7) 16 (88.9)
Other 31 (17.8) 18 (20.6) 6 (11.3) 5 (29.4) 2 (11.1)
Functionally dependent, n(%) 70 (61.4) 33 (70.2%) 24 (60.0) 6 (60.0) 7 (41.2) 0.211a
Type of diabetes, n(%) < 0.001c
Type 1 18 (10.2) 18 (20.5) 0 (0.0) 0 (0.0) 0 (0.0)
Type 2 152 (86.4) 64 (72.7) 53 (100.0) 17 (100.0) 18 (100.0)
Other form of diabetes 6 (3.4) 6 (6.8) 0 (0.0) 0 (0.0) 0 (0.0)
Diabetes duration, median (min;max), (years) 11.0 (0.0;52.0) 17.0 (0.7;52.0) 9.0 (0.0;47.0) 1.0 (1.0;30.0) 18.0 (1.0;45.0) < 0.001b
Diabetes management, n(%) 0.383a
Solely managed by self 75 (42.6) 36 (40.9) 23 (43.4) 10 (58.8) 6 (33.3)
Solely managed by other 52 (29.5) 22 (25.0) 19 (35.8) 4 (23.5) 7 (38.9)
Occasional assistance 49 (27.8) 30 (34.1) 11 (20.8) 3 (17.6) 5 (27.8)
Usual diabetes outpatient care, n(%)d < 0.001c
Primary healthcare 111 (63.1) 40 (45.5) 50 (94.3) 10 (58.8) 11 (61.1)
Hospital outpatient 45 (25.6) 35 (39.8) 0 (0.0) 5 (29.4) 5 (27.8)
Private consultation 7 (4.0) 5 (5.7) 1 (1.9) 0 (0.0) 1 (5.6)
Other 11 (6.3) 8 (9.1) 0 (0.0) 2 (11.8) 1 (5.6)
Without follow-up 2 (1.1) 0 (0.0) 2 (3.8) 0 (0.0) 0 (0.0)
Chronic diabetes complications, n(%)d
Eye complications 63 (50.0) 43 (62.3) 12 (40.0) 3 (20.0) 5 (41.7) 0.011a
Neuropathy 29 (26.1) 17 (27.9) 6 (21.4) 1 (9.1) 5 (45.5) 0.249c
Nephropathy 74 (47.4) 37 (48.1) 25 (53.2) 5 (31.3) 7 (43.8) 0.493a
Lower limb complications 24 (15.9) 16 (20.8) 4 (8.9) 2 (13.3) 2 (14.3) 0.393c
Known atherosclerotic disease 66 (47.8) 30 (44.8) 19 (46.3) 7 (46.7) 10 (66.7) 0.488a
Coronary heart disease 32 (57.1) 17 (63.0) 8 (53.3) 3 (50.0) 4 (50.0) 0.848c
Cerebrovascular disease 31 (55.4) 15 (57.7) 12 (70.6) 3 (50.0) 1 (14.3) 0.092c
Motor complications 19 (33.3) 11 (42.3) 6 (33.3) 1 (16.7) 1 (14.3) 0.462c
Peripheral artery disease 25 (61.0) 10 (58.8) 6 (54.5) 3 (50.0) 6 (85.7) 0.535c
Other atherosclerotic dis 8 (21.1) 4 (23.5) 1 (9.1) 1 (20.0) 2 (40.0) 0.612c
Previous hypoglycemia in last 12months, n(%) 58 (47.5) 39 (66.1) 11 (28.9) 4 (30.8) 4 (33.3) 0.001a
SD Standard deviation
a Chi-square test; b Kruskal-Wallis test; c Monte Carlo methods; d Each patient can have more than one
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63 patients (36.0%) had a repeated hypoglycemia during
hospitalization, none of which led to further complica-
tions. The relative frequency of patients with
hypoglycemia during the hospitalization was 47.1% on
insulin-based patients, 26.4% on secretagogue-based
patients, 29.4% on non-secretagogue and 16.7% on insu-
lin+secretagogue patients (p = 0.018). There were no
statistical differences in the length of stay or
hospitalization outcome, however there were more
deaths in the insulin-based patients.
The risk factors for hypoglycemia and the risk factors
for complications following an event were also assessed.
The most frequent risk factor was polypharmacy (> 5
distinct drugs), in 85.0% of patients, followed by age >
75 years (49.4%). Age > 75 years was statistically different
between treatment groups with 72.2% patients from
insulin+secretagogue and 35.3% patients from non-
secretagogue regimen (p = 0.017). Heart failure was the
most frequently reported (28.9%) risk factor for compli-
cations after an event (Table 2).
The median time spent by patients in the ER was
approximately 9.1 h and 146.6 h/6.1 days in the ward.
Approximately 64% of patients were discharged back
home, while 17.6% went to an institution/another hos-
pital and 4.5% (8 patients) died (Table 2). About 43% of
the patients were referred to hospital diabetes/endocrin-
ology outpatient clinic and 32.9% to the general
practitioner.
Hypoglycemia literacy
Patients were evaluated on their knowledge of identify-
ing, treating and preventing a hypoglycemia event
(hypoglycemia literacy questionnaire). The questionnaire
was answered by 77.1% (n = 135) of patients and 22.9%
(n = 40) of caregivers. Approximately 75% (n = 132) of
the patients knew ‘what is a hypoglycemia, ‘hypo’ or ‘a
drop in blood sugar’. From these, 90.9% (n = 120) knew
‘how to identify it’, 84.8% (n = 112) knew ‘what to do in
case of hypoglycemia’ (98.2% (n = 110) answered ‘ingest
a form of simple carbohydrate’) and 63.6% (n = 84) knew
‘what to do to prevent it’.
Subgroup analyses by type of diabetes
In the study population, 86.4% of patients had T2DM,
10.2% T1DM and 3.4% had another form of diabetes
(3 patients ‘post pancreatectomy’, 1 patient ‘after sur-
gery’, 1 patient ‘secondary’ and 1 patient ‘secondary
to pancreatitis’). Due to its small size, the group
‘other type of diabetes’ was excluded from the infer-
ential analysis. Characterization by type of diabetes is
described on Table 3.
Among T1DM patients, higher statistical differences
between groups were found for disease duration (median
22.0 vs 10.0 years), diabetes management by self (72.2%
vs 38.2%), eye and neuropathy complications (81.3% vs
46.2%; 50.0% vs 20.9%), and hypoglycemia in the last 12
months (85.7% vs 40.4%).
For T2DM patients statistically significant differences
were found for age (78.0 vs 49.5), BMI (26.3 vs 22.9 kg/m2),
primary healthcare follow-up (68.4% vs 22.2%), atheroscler-
otic disease complication (51.7% vs 14.3%), and polyphar-
macy as risk factor (90.0% vs 41.2%).
Discussion
In the HIPOS-WARD study we evaluated patients with
diabetes and a hypoglycemic episode that caused a
hospitalization, focusing on the clinical characterization.
The hypoglycemia/hyperglycemia ratio was 0.27 for all
DM patients and 0.38 in T2DM patients. For each
hypoglycemia episode, there were approximately 4
hyperglycemic emergencies for all DM patients, and 3
for T2DM patients. These results were not as expected,
and might be explained due to the safer and more effect-
ive state of hypoglycemia drugs, which lead to its
decreasing occurrence. Additionally, the burden of
hypoglycemia in inpatients in Portugal appears to be
relevant but lower than the burden of hyperglycemia
both in T1DM and T2DM. As no longitudinal data is
available it is unknow how the situation has evolved over
recent years. Lipska et al. [5] described between 1999
and 2011 in the USA a steady increase of admissions
due to hypoglycemia, eventually overtaking admissions
due to hyperglycemia in the first decade of this century.
However, this was before therapies with a lower poten-
tial of hypoglycemia (DPP4i, SGLT2i and GLP1
analogues) were introduced or widely used [18, 19]. It is
unknown if wider use of these agents, as well as decreas-
ing use of SU type drugs and growing awareness of the
risk of hypoglycemia reversed the trend once more.
More recent insulin formulations are also associated
with lower rates of hypoglycemia in T1DM and in some
settings for T2DM [20–22]. In Portugal the use of anti-
hyperglycemic agents with a low risk of hypoglycemia—
DPP4i in particular—has increased substantially since
early in the twenty-first century representing 25% of all
oral drugs in 2015, while SU’s dropped from 54% in
2000 to 20% in 2015 [3]. Furthermore, increased aware-
ness of hypoglycemia conveyed by national and inter-
national guidelines [21, 23] as well as the national
studies HIPOS-ER [13], on severe hypoglycemia and
HIPOS-PHARMA [24], a pharmacy level evaluation of
mild/moderate hypoglycemia, might have contributed to
a blunting in the rates of hypoglycemia. Also, glycemic
target achievement in the National Health System
(NHS) primary care has improved between 2010 and
2015 [3, 12]. This, overall, might suggest the importance
of anti-hyperglycemic agent with a lower risk of
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Table 2 Hypoglycemia episode characterization, overall and by class of anti-hyperglycemic agent
Total
(n = 176)














Hypoglycemia episode, n(%) 176 (100.0) 88 (50.0) 53 (30.1) 17 (9.7) 18 (10.2)
HbA1c, median (min;max)(%) 6.9 (4.0;27.0) 7.6 (4.6;27.0) 5.8 (4.0;14.2) 5.8 (4.6;9.9) 7.0 (5.4;10.3) <
0.001b
Lowest glycemia, median (min;max)
(mg/dL)
74.0 (20.0;268.0) 56.0 (20.0;268.0) 80.0 (30.0;159.0) 76.5 (39.0;170.0) 91.5 (25.0;160.0) 0.041b
Complications as result of hypo, n(%) 26 (14.9) 15 (17.2) 7 (13.2) 0 (0.0) 4 (22.2) 0.240c
Major trauma 3 (11.5) 3 (20.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.719c
Acute atherosclerotic event 1 (3.8) 1 (6.7) 0 (0.0) 0 (0.0) 0 (0.0) > 0.999c
Other CV event 4 (15.4) 1 (6.7) 1 (14.3) 0 (0.0) 2 (50.0) 0.137c
Neurologic 6 (23.1) 6 (40.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.089c
Infection 6 (23.1) 4 (26.7) 1 (14.3) 0 (0.0) 1 (25.0) > 0.999c
Other 9 (34.6) 3 (20.0) 5 (71.4) 0 (0.0) 1 (25.0) 0.055c
Repeated hypo during hospitalization,
n(%)
63 (36.0) 41 (47.1) 14 (26.4) 5 (29.4) 3 (16.7) 0.018a








168.6 (34.7;935.0) 165.7 (34.4;
1583.7)
0.275b
Discharge destination, n(%) 0.198c
Home 113 (64.2) 52 (59.1) 40 (75.5) 11 (64.7) 10 (55.6)
Ambulatory 24 (13.6) 17 (19.3) 2 (3.8) 2 (11.8) 3 (16.7)
Institution 30 (17.0) 12 (13.6) 10 (18.9) 3 (17.6) 5 (27.8)
Other hospital 1 (0.6) 1 (1.1) 0 (0.0) 0 (0.0) 0 (0.0)
Death 8 (4.5) 6 (6.8) 1 (1.9) 1 (5.9) 0 (0.0)
Risk factors for hypoglycemia, n(%)e
> 75 years 87 (49.4) 36 (40.9) 32 (60.4) 6 (35.3) 13 (72.2) 0.017a
Dementia 28 (16.7) 11 (13.4) 11 (21.2) 2 (12.5) 4 (22.2) 0.543c
Major sensorial impairment
Blindness 13 (7.4) 9 (10.3) 2 (3.8) 0 (0.0) 2 (11.1) 0.297c
Deafness 6 (3.4) 2 (2.3) 1 (1.9) 0 (0.0) 3 (16.7) 0.050c
Hypothyroidism 14 (10.1) 9 (13.4) 3 (7.3) 1 (7.1) 1 (6.3) 0.811c
Adrenal failure 3 (2.2) 2 (2.9) 0 (0.0) 1 (7.1) 0 (0.0) 0.267c
Severe renal failure 19 (38.0) 11 (39.3) 4 (25.0) 1 (50.0) 3 (75.0) 0.263c
Hepatic failure 7 (4.1) 5 (5.9) 2 (3.8) 0 (0.0) 0 (0.0) 0.875c
Cachexia/significant malnourishment 19 (10.9) 15 (17.2) 2 (3.8) 1 (6.3) 1 (5.6) 0.068d
Brittle diabetes 21 (14.9) 15 (23.1) 4 (9.3) 2 (12.5) 0 (0.0) 0.049c
Weaning of corticosteroid drugs 10 (5.8) 4 (4.7) 1 (1.9) 4 (23.5) 1 (5.6) 0.025c
Previous hypo in last 12 months 58 (47.5) 39 (66.1) 11 (28.9) 4 (30.8) 4 (33.3) 0.001a
Lifestyle factors
Irregular meals 52 (37.1) 28 (36.8) 13 (32.5) 6 (54.5) 5 (38.5) 0.606c
Shift work 4 (2.4) 4 (4.7) 0 (0.0) 0 (0.0) 0 (0.0) 0.515c
Other 7 (4.0) 5 (5.7) 2 (3.8) 0 (0.0) 0 (0.0) 0.872c
Polypharmacy 147 (85.0) 69 (81.2) 45 (84.9) 16 (94.1) 17 (94.4) 0.412c
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hypoglycemia in containing the risk of severe
hypoglycemia.
HIPOS-WARD only focused on the most severe
hypoglycemia occurrences that lead to hospitalization
and identified its clinical and economic burden [25] but
does not cover the entire scope of the hypoglycemia
problem.
Unfortunately, the lack of longitudinal data in
Portugal cannot exclude the possibility–although
unlikely–that the rate of hypoglycemia is still increas-
ing. Irrespective of the causes our data reinforces the
importance of anti-hyperglycemic agent with a low risk
of hypoglycemia either as a contributing factor to curb
it’s putative increase or to limit a future increase.
HIPOS-WARD reinforces the relevance of these
therapies: the occurrence of hypoglycemic episodes was
higher in patients on an insulin-based therapy followed
by those on a secretagogue-based therapy, which are
indeed associated to additional side effects and an
increased risk of hypoglycemia [26–28]. Insulin+secreta-
gogue therapy accounted for 10.2% of the sample and
9.7% were on non-secretagogue regimen. Therapeutic
regimens based on or including secretagogues were
more common in elderly patients and those followed in
primary healthcare, which might be associated to treat-
ment cost restrictions or related to clinical inertia. Drug
prescription is indifferently managed by specialists/GPs
and new antidiabetic drugs can be freely prescribed by
all physicians. Although these patients are mostly seen
at a primary care setting they are usually evaluated by
in-hospital consultation when they fail to achieve control
and need to add injectable therapy—like insulin—to
their care or when they show complications from the
disease. Our findings have shown that the insulin+se-
cretagogue based therapy group was statistically associ-
ated with risk factors including disease duration and age,
having higher proportion of patients with coronary heart
disease, peripheral artery disease and osteoporosis. Also,
a large group of patients reported nephropathy, a con-
ventional risk factor for hypoglycemia in people with
diabetes, due to multiple factors as the decrease of insu-
lin clearance and it’s degradation in peripheral tissues,
reduction in glycogen stores, reduced renal gluconeo-
genesis [29–31]. Also, commonly used antidiabetic drugs
are renally excreted and have a prolonged half-life in
patients with CKD, predisposing them to episodes of
hypoglycemia. The confluence of these factors may con-
tribute to a greater risk for hypoglycemia among patients
with CKD and may be an unintended consequence of
therapy to treat hyperglycemia in these patients [32].
Patients on secretagogue-based therapy had a higher
proportion of cerebrovascular disease and heart failure.
Again, this denotes the frailty of patients at higher risk
of hypoglycemia and the importance of adopting strat-
egies and therapies that minimize its risk [33, 34]. The
actual increasing number of new AHAs with an intrinsic
low risk of hypoglycemia are an important therapeutic
option, however, patients and caregivers education are
also crucial [35, 36].
This study also included T1DM patients, representing
the first Portuguese national dataset on this population.
Patients with T1DM, due to intensive insulin therapy,
are usually associated with a higher risk of hypoglycemia
[10] and in our study 85.7% of T1DM vs only 40.4% of
T2DM had a hypoglycemic episode in previous 12
months. However, during the study period only 10.2% of
the total hypoglycemia admissions were in T1DM and
so hypoglycemia in T2DM represented the biggest bur-
den of hypoglycemia events requiring hospitalization,
highlighting that hypoglycemia is a very relevant issue in
T2DM. It is well known that hypoglycemia triggered by
secretagogues can be long-lasting, more severe and
recurrent. Although expected, this data also shows that
T1DM have a higher burden of microvascular complica-
tions whereas T2DM more atherosclerotic complica-
tions. This data alert to the importance of a patient
Table 2 Hypoglycemia episode characterization, overall and by class of anti-hyperglycemic agent (Continued)
Total
(n = 176)














High risk for complications after the event
Coronary heart disease 32 (25.0) 17 (26.6) 8 (21.6) 3 (21.4) 4 (30.8) 0.897c
Cerebrovascular disease 31 (24.2) 15 (23.8) 12 (30.8) 3 (21.4) 1 (8.3) 0.613c
Heart failure 48 (28.9) 20 (23.8) 19 (36.5) 3 (23.1) 6 (35.3) 0.372d
Peripheral artery disease 25 (22.1) 10 (18.5) 6 (18.2) 3 (21.4) 6 (50.0) 0.151c
Osteoporosis 8 (7.6) 3 (5.4) 3 (10.0) 1 (9.1) 1 (12.5) 0.518c
Living alone 33 (18.8) 19 (21.6) 8 (15.1) 4 (23.5) 2 (11.1) 0.642c
a Chi-square test; b Kruskal-Wallis test; c Monte Carlo methods; d Fisher’s exact test; e Each patient can have more than one; Polyphramacy: > 5 distinct drugs, for
one or more conditions
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Table 3 Characterization by type of diabetes
Total
(n = 176)





Hypoglycemia episode, n(%) 176 (100.0) 18 (10.2) 152 (86.4)
Gender (female), n(%) 97 (55.1) 6 (33.3) 88 (57.9) 0.048a
Age, median (min;max), (years) 75.0 (28;98) 49.5 (28.0;74.0) 78.0 (35.0;98.0) < 0.001b
BMI, median (min;max), (kg/m2) 26.0 (4.6) 22.9 (18.4;31.6) 26.3 (15.6;38.8) 0.009d
Diabetes duration, median (min;max), (years) 11.0 (0.0;52.0) 22.0 (4.0;52.0) 10.0 (0.0;51.0) 0.001b
Diabetes management, n(%) 0.013a
Solely managed by self 75 (42.6) 13 (72.2) 58 (38.2)
Solely managed by other 52 (29.5) 1 (5.6) 50 (32.9)
Occasional assistance 49 (27.8) 4 (22.2) 44 (28.9)
Usual diabetes outpatient care, n(%)f 0.001c
Primary health care 111 (63.1) 4 (22.2) 104 (68.4)
Hospital outpatient 45 (25.6) 11 (61.1) 31 (20.4)
Private consultation 7 (4.0) 1 (5.6) 6 (3.9)
Other 11 (6.3) 2 (11.1) 9 (5.9)
Without follow-up 2 (1.1) 0 (0.0) 2 (1.3)
Chronic diabetes complications, n(%)f
Eye complications 63 (50.0) 13 (81.3) 48 (46.2) 0.014e
Neuropathy 29 (26.1) 7 (50.0) 19 (20.9) 0.040e
Nephropathy 74 (47.4) 6 (37.5) 67 (49.6) 0.359a
Lower limb complications 24 (15.9) 2 (11.8) 20 (15.6) > 0.999e
Known atherosclerotic disease 66 (47.8) 2 (14.3) 62 (51.7) 0.008a
Coronary heart disease 32 (57.1) 2 (100.0) 29 (55.8)
Cerebrovascular disease 31 (55.4) 1 (100.0) 30 (56.6)
Motor complications 19 (33.3) 0 (0.0) 19 (35.8)
Peripheral artery disease 25 (61.0) 1 (100.0) 24 (63.2)
Other atherosclerotic dis 8 (21.1) 0 (0.0) 7 (20.0)
Previous hypoglycemia in last 12months, n(%) 58 (47.5) 12 (85.7%) 42 (40.4%) 0.001a
Repeated hypo during hospitalization, n(%) 63 (36.0) 7 (41.2%) 51 (33.6%) 0.530a
Length of stay in ward, median (min;max)(h) 146.6 (1.6;1782.3)
Discharge destination, n(%) 0.052c
Home 113 (64.2) 13 (72.2) 98 (64.5)
Ambulatory 24 (13.6) 5 (27.8) 16 (10.5)
Institution 30 (17.0) 0 (0.0) 29 (19.1)
Other hospital 1 (0.6) 0 (0.0) 1 (0.7)
Death 8 (4.5) 0 (0.0) 8 (5.3)
Risk factors for hypoglycemia, n(%)f
> 75 years 87 (49.4) 0 (0.0) 86 (56.6) < 0.001a
Dementia 28 (16.7) 0 (0.0) 28 (19.0) 0.081e
Major sensorial impairment
Blindness 13 (7.4) 4 (23.5) 8 (5.3) 0.021e
Deafness 6 (3.4) 1 (5.9) 5 (3.3) 0.476e
Hypothyroidism 14 (10.1) 3 (18.8) 11 (9.4) 0.376e
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centered approach to choosing appropriate pharmaco-
logic treatment of blood glucose, including important
comorbidities such as atherosclerotic cardiovascular dis-
ease. The rates of microvascular complications in T2DM
ranged between 20.9–46.2% underscoring the import-
ance of glycemic control on both groups in order to
prevent these complications with great impact in quality
of life [37–39].
Elderly, functionally dependent individuals (frail/non-
frail) are exposed [40] and identified to have higher risk
of hypoglycemia [10, 16, 33, 41–44]. Therefore, these
patients should be cared for in a different way to miti-
gate the risk of this and other adverse events. Our
results are consistent with a ward admitted patient
population having T2DM, predominantly elderly, frail,
with multiple comorbidities and moderately dependent,
mainly treated with insulin and secretagogues. These
hospitalizations were frequently preceded by similar and
recent episodes, which reinforces the idea that these
patients usually present recurrent hypoglycemia
episodes, increasing the risk to develop complications at
each occurrence. Moreover, more than half of patients
need help (total/partial) to manage their diabetes treat-
ment, denoting the frailty of these individuals at high
risk of inadequate use of drugs and consequently at risk
of having more severe episodes related to uncontrolled
glycemia. The main risk factors for a hypoglycemia event
were polypharmacy (> 5 distinct drugs, for one or more
conditions) [45, 46] and age > 75 years, and heart failure
was the most frequent risk factor for complications after
an event.
Results are consistent with HIPOS-ER study [13],
which triggered HIPOS-WARD by showing that, in a
setting of ER, more than 40% of T2DM patients with
severe hypoglycemia had been hospitalized as conse-
quence of the event.
Overall, our data suggests that while hyperglycemia
is still the major cause of hospital admissions for both
types of diabetes, over 60% of all hypoglycemia ad-
missions happened in patients with functional impair-
ment and, in T2DM, elderly patients. This
underscores that there is still work to be done in
terms of avoiding clinical inertia and recurrence of
hypoglycemic events in this patient group, questioning
the use of secretagogue-based therapy and some com-
binations like SU + insulin, reinforcing the importance
to increase the number of anti-hyperglycemic agents
with low risk of hypoglycemia as a therapeutic option
[35, 36] and developing educational and/or support
programs for patients/caregivers, especially designed
Table 3 Characterization by type of diabetes (Continued)
Total
(n = 176)





Adrenal failure 3 (2.2) 1 (7.1) 2 (1.7) 0.288e
Severe renal failure 19 (38.0) 2 (40.0) 17 (38.6) NA
Hepatic failure 7 (4.1) 0 (0.0) 7 (4.7) > 0.999e
Cachexia/significant malnourishment 19 (10.9) 3 (17.6) 12 (7.9) 0.181e
Brittle diabetes 21 (14.9) 6 (46.2) 13 (10.5) 0.003e
Weaning of corticosteroid drugs 10 (5.8) 1 (5.9) 9 (6.0) > 0.999e
Previous hypo in the last 12 months 58 (47.5) 12 (85.7) 42 (40.4) 0.001a
Lifestyle factors
Irregular meals 52 (37.1) 8 (50.0) 41 (34.7) 0.235a
Shift work 4 (2.4) 3 (18.8) 1 (0.7) 0.003e
Other 7 (4.0) 1 (5.9) 5 (3.3) 0.478e
Polypharmacy 147 (85.0) 7 (41.2) 135 (90.0) < 0.001e
High risk for complications after the event
Coronary heart disease 32 (25.0) 2 (14.3) 29 (26.4) 0.514e
Cerebrovascular disease 31 (24.2) 1 (7.7) 30 (27.0) 0.182e
Heart failure 48 (28.9) 0 (0.0) 48 (33.6) 0.004a
Peripheral artery disease 25 (22.1) 1 (7.7) 24 (25.0) 0.291e
Osteoporosis 8 (7.6) 1 (6.7) 7 (8.1) > 0.999e
Living alone 33 (18.8) 9 (50.0) 22 (14.5) 0.001e
a Chi-square test; b Kruskal-Wallis test; c Monte Carlo approach; d ANOVA; e Fisher’s exact test; f Each patient can have more than one; Polyphramacy: > 5 distinct
drugs, for one or more conditions
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for populations at higher risk, in order to minimize
the risk for complications.
Overall, the most likely causes of hypoglycemia
were due to carbohydrate deficit, by a cause second-
ary to acute illness or related to insulin therapy.
These potential causative factors should be addressed
by systematically discussing it with all patients who
are at increased risk of hypoglycemia as well as with
their caregivers. For three quarters of patients
hypoglycemia was the main driver for ward admission
and the most frequent complications as result of the
hypoglycemia episode that triggered the admission
were neurologic and infection. This might indicate
the Portuguese NHS approach by both specialists and
primary care providers might have curbed the rates of
hypoglycemia despite improving in diabetes target
achievement. The growing use of new antihyperglyce-
mic drug classes which have an intrinsic lower risk of
hypoglycemia might be contributing to a decrease in
the prevalence of severe hypoglycemia.
This study was not randomized or controlled, there-
fore results are primarily descriptive. Its observational
nature may be considered a limitation and since no
individual drug level information has been collected
(only anti-hyperglycemic agent therapy group as pre-
determined), it was not possible to determine specific
causal associations. In order to minimize selection
bias, patients were enrolled in a consecutive manner,
in different centers throughout the country, which
gives a wider overview of the information collected
[41, 42]. However, there was clearly a higher number
of T2DM patients and a low number of patients on
non-secretagogue and insulin+secretagogue therapies
in this study.
As a strength of the study we point out the specific
tools (study questionnaire and literacy questionnaire)
designed to adequately capture the information in
accordance with its cross-sectional nature [44, 47]. Also,
this study was part of an integrated series designed to
evaluate adult patients with diabetes in pharmacies–
HIPOS-PHARMA [24], in the emergency room–HIPOS-
ER [13, 14], and hospitalized–HIPOS-WARD, contribut-
ing to a full country perspective.
In conclusion, in this study hyperglycemic emer-
gencies were more frequent while the lack of longi-
tudinal data doesn’t allow for trend projection.
Elderly T2DM patients with functional impairment
represent the bulk of admissions for hypoglycemia,
highlighting there is still the need to optimize ther-
apy in terms of the potential for hypoglycemia in
this patient group, balancing glycemic target achieve-
ment with hypoglycemia avoidance. The study con-
firms higher rates of hypoglycemia in T1DM,
highlighting the critical problem this complication
represents, the overwhelming contribution of T2DM
to the total burden, and the importance of this com-
plication for both patients and the National Health
System. Future efforts should also be taken to better
characterize and prevent hyperglycemic occurrences
especially in T2DM patients.
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